GLP-1 CollectiveMedicare and Medicaid
What government
coverage actually does.
Two programmes, two completely different answers. Medicare is federal and the answer is the same everywhere, and right now that answer is a programme that caps what you pay at $50 a month whatever your dose. Medicaid is run by each state, so the answer changes at the state line, and the map further down is what your state actually covers.
Medicare GLP-1 Bridge
Fifty dollars a month, through the end of 2027.
The Bridge is a demonstration run by the Centers for Medicare and Medicaid Services. It gives eligible Part D beneficiaries access to certain GLP-1 medications approved for weight reduction at a fifty dollar monthly copayment, and it runs from 1 July 2026 through 31 December 2027. Your Part D plan does not have to opt in for you to use it.
How to find out if you qualify
Medicare publishes the eligibility criteria and a checker at medicare.gov/glp1bridge, and you can call 1-800-MEDICARE, which is 1-800-633-4227. We do not administer this program and cannot check eligibility for you.
What it does not do
The fifty dollars does not count toward your Part D deductible, and it does not count toward the annual out-of-pocket limit on prescription drugs. There is no low-income subsidy applied to it. The copay stays flat as your dose increases, which is the opposite of how self-pay pricing works.
Source. The program terms above are from the CMS page for the Medicare GLP-1 Bridge, read on 4 September 2026. It is a time-limited demonstration, so the end date matters.
The rule that surprises people
Manufacturer savings cards are closed to you.
Every copay card from Lilly and Novo Nordisk excludes anyone enrolled in Medicare, Medicaid, TRICARE, the VA or any other government health program. This is federal law rather than a company policy, so nobody at the pharmacy can make an exception.
Two doors stay open. You may buy at the self-pay price outside your insurance entirely, paying the manufacturer directly and claiming nothing through Medicare, which the cash-pay page prices out. You may also apply for charitable assistance from an independent foundation, which is one of the few kinds of help people on Medicare are able to accept, and prescription assistance lists the two we send people to.
Medicaid
Fifty-one different answers.
Every state Medicaid programme covers GLP-1 medications for type 2 diabetes, because it has to. Covering them for weight is a separate decision each state makes for itself, and five states have ended or cut back that coverage since January while two others added it.
For type 2 diabetes, Medicaid already covers these. Everywhere.
Every state Medicaid programme in the country covers GLP-1 medications for type 2 diabetes, because federal rules require it once a manufacturer signs the national rebate agreement. What each state decides for itself is whether to cover the same medications for weight, which is what the map below shows.
How the covered version works in practice. Your prescriber writes for the product your state prefers, and asking which GLP-1 that is saves more time than any other question. The pharmacy then runs a prior authorization, which normally means sending the diagnosis, a recent A1C and what you have already tried, and which is a step rather than a denial. If your Medicaid comes through a managed care plan rather than the state directly, that plan can add its own preferred list, so ask it for the GLP-1 criteria in writing. A denial can be appealed, Medicaid appeals have deadlines that favour you, and many denials are about missing paperwork rather than about you.
Coverage for obstructive sleep apnea or for reducing cardiovascular risk is decided separately again, so a no for weight is not always a no.
Pick a state
Read the payment numbers carefully. They carry no diagnosis, so they cannot tell you whether a state paid for weight, diabetes, sleep apnea or heart risk, and they say nothing about whether the patient was an adult or a teenager. Wegovy is approved for cardiovascular risk and Zepbound for obstructive sleep apnea, so every state pays for a few of both whatever its weight policy is. What is worth reading is the share: states that cover these for weight send a third to two thirds of their GLP-1 volume to the weight-approved products, and states that do not send under one in ten. The data is published one to two quarters behind, and counts under eleven prescriptions are withheld by CMS and shown as paid with the number held back rather than as zero. This map was built by GLP-1 Coach (glp1coach.app) and is provided to the GLP-1 Collective free of charge, and the same map lives on the coaching site and in the Toolbox inside GLP-1 Community Cozy Butter, which is free to join. GLP-1 Coach and GLP1Laws are operated by GLP-1 Studio LLC and Cozy Butter by Cozy Butter LLC, all founded or co-founded by the Collective's Executive Director. The Collective pays nothing for any of it and receives no payment for showing it. How this works.
If your state says diabetes only
That is a reason to ask rather than a reason to stop. A GLP-1 prescribed for type 2 diabetes is covered in every state, coverage for obstructive sleep apnea or cardiovascular risk is decided separately from weight, and a state can change its policy between the date on this page and the day you call. Your state Medicaid office and your own managed care plan are the authorities on today, and what your plan is deciding covers how to ask. Our policy tracker follows the changes as they are announced.